Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation
Zhao X.,Affiliated Hospital of PLA General Hospital |
Zhu G.,General Hospital of the Air Force of Peoples Liberation Army |
Chen H.,Second Artillery General Hospital of Peoples Liberation Army |
Yang P.,Navy General Hospital of Peoples Liberation Army |
And 3 more authors.
Journal of Cancer Research and Therapeutics | Year: 2014
Objective: This study aimed to investigate the potential use of icotinib as first-line treatment to prevent brain metastasis from advanced lung adenocarcinoma.Patients and Methods: This investigation was designed as a retrospective nonrandomized controlled study. Enrolled patients received either icotinib or traditional chemotherapy as their first-line treatment. The therapeutic efficacy was compared among patients with advanced (stages IIIB and IV) lung adenocarcinoma with epidermal growth factor receptor (EGFR)-sensitive mutation. The primary endpoint was the cumulative incidence of brain metastasis, whereas the secondary endpoint was overall survival (OS). Death without brain metastasis was considered a competitive risk to calculate the cumulative risk of brain metastasis. Survival analysis was conducted using the Kaplan-Meier method and statistical significance were determined using the log-rank test.Results: The present study included 396 patients with 131 in the icotinib group and 265 in the chemotherapy group. Among those with EGFR-sensitive mutation, the cumulative risk of brain metastasis was lower in the icotinib group than in the chemotherapy group. However, no significant difference in OS was observed between the two groups.Conclusion: Icotinib can effectively reduce the incidence of brain metastasis and therefore improve prognosis in advanced lung adenocarcinoma patients with EGFR-sensitive mutation. Source
Fu Y.,Affiliated Hospital of PLA General Hospital |
Kang H.,Affiliated Hospital of PLA General Hospital |
Zhao H.,Affiliated Hospital of PLA General Hospital |
Hu J.,Affiliated Hospital of PLA General Hospital |
And 4 more authors.
International Journal of Clinical and Experimental Medicine | Year: 2015
Purpose: This study evaluated the efficacy and adverse effects of Imatinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) and Sunitinib therapy to advanced Dermatofibrosarcoma protuberan (DFSP) after Imatinib resistance. Methods: We analyzed the efficacy, adverse effects and survival of 95 patients with locally advanced or metastatic DFSP treated by Imatinib between January 2003 and December 2009, and also analyzed the efficacy and adverse effects of 30 patients after Imatinib failure between January 2008 and December 2011. Results: In all 95 patients treated by Imatinib, 16 had complete response (CR, 16.8%), 44 had partial response (PR, 46.3%), 23 had stable disease (SD, 24.2%) and 12 had progressive disease (PD, 12.6%). The DCR (CR+PR+SD) was 87.4%. The median PFS was 23 months and the OS was 40 months. For 30 patients had Sunitinib treatment after Imatinib failure, 2 had CR (6.7%), 10 had PR (33.3%), 12 had SD (40%) and 6 had PD (20%). The disease control rate (DCR=CR+PR+SD) was 73.3%. The progression free survival (PFS) of CR and PR patients were 22 months and 20 months respectively. The PFS of 12 SD was 18 months, and overall survival (OS) was 28 months. And the median PFS and OS of all 30 patients were 19 and 27 months respectively after Sunitinib treatment. Most of the Imatinib-induced adverse effects are of grade 1-2, including nausea, water retention/edema, fatigue, etc. Conclusion: Imatinib has been proven to be effective and well-tolerated in the treatment of locally advanced or inoperable patients with DFSP. After Imatinib failure, Sunitinib therapy showed good clinical efficacy and tolerated adverse effects as a new treatment option for such patients. © 2015, E-Century Publishing Corporation. All Rights Reserved. Source